Long-Term Safety of a Coordinated Delivery Tablet of Enteric-Coated Aspirin 325 mg and Immediate-Release Omeprazole 40 mg for Secondary Cardiovascular Disease Prevention in Patients at GI Risk

Low-Dose Acetylsalicylic Acid Use and the Risk of Upper Gastrointestinal Bleeding: A Meta-Analysis of Randomized Clinical Trials and Observational Studies

(2016) Vera E Valkhoff et al.   CANADIAN JOURNAL OF GASTROENTEROLOGY

Time-trends in the prescribing of gastroprotective agents to primary care patients initiating low-dose aspirin or non-steroidal anti-inflammatory drugs: a population-based cohort study

(2015) Margaretha F. Warlé-van Herwaarden et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Risk of Upper and Lower Gastrointestinal Bleeding in Patients Taking Nonsteroidal Anti-inflammatory Drugs, Antiplatelet Agents, or Anticoagulants

(2015) Ángel Lanas et al.   Clinical Gastroenterology and Hepatology

PA32540 (a coordinated-delivery tablet of enteric-coated aspirin 325 mg and immediate-release omeprazole 40 mg) versus enteric-coated aspirin 325 mg alone in subjects at risk for aspirin-associated gastric ulcers: Results of two 6-month, phase 3 studies

(2014) David J. Whellan et al.   AMERICAN HEART JOURNAL

Low-Dose Aspirin and Non-steroidal Anti-inflammatory Drugs Increase the Risk of Bleeding in Patients with Gastroduodenal Ulcer

(2014) Keisuke Kawasaki et al.   DIGESTIVE DISEASES AND SCIENCES

Guidelines for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack

(2014) Walter N. Kernan et al.   STROKE

Patient-reported adherence to coprescribed proton pump inhibitor gastroprotection in osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis patients using nonsteroidal anti-inflammatory drugs

(2014) Kenneth Henriksson et al.   Patient Preference and Adherence

Intragastric acidity and omeprazole exposure during dosing with either PA32540 (enteric-coated aspirin 325 mg + immediate-release omeprazole 40 mg) or enteric-coated aspirin 325 mg + enteric-coated omeprazole 40 mg - a randomised, phase 1, crossover study

(2013) P. B. Miner et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Effect of Baseline Gastrointestinal Risk and Use of Proton Pump Inhibitors on Frequency of Discontinuation of Aspirin for Secondary Cardiovascular Prevention in United Kingdom Primary Care

(2013) Elisa Martín Merino et al.   AMERICAN JOURNAL OF CARDIOLOGY

2012 ACCF/AHA Focused Update Incorporated Into the ACCF/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial Infarction

(2013) et al.   CIRCULATION

Low-Dose Aspirin and Upper Gastrointestinal Bleeding in Primary Versus Secondary Cardiovascular Prevention: A Population-Based, Nested Case-Control Study

(2013) K. J. Lin et al.  

Low-dose acetylsalicylic acid and gastrointestinal ulcers or bleeding - a cohort study of the effects of proton pump inhibitor use patterns

(2013) J. Hedberg et al.   JOURNAL OF INTERNAL MEDICINE

Suboptimal prescribing of proton-pump inhibitors in low-dose aspirin users: a cohort study in primary care

(2013) Hilda J I de Jong et al.   BMJ Open

Burden of Upper Gastrointestinal Symptoms in Patients Receiving Low-Dose Acetylsalicylic Acid for Cardiovascular Risk Management

(2012) Peter Bytzer et al.   American Journal of Cardiovascular Drugs

Adherence to gastroprotection during cyclooxygenase 2 inhibitor treatment and the risk of upper gastrointestinal tract events: A population-based study

(2012) Vera E. Valkhoff et al.   ARTHRITIS AND RHEUMATISM

Risk factors for gastrointestinal bleeding associated with low-dose aspirin

(2012) Vera E. Valkhoff et al.   BEST PRACTICE & RESEARCH IN CLINICAL GASTROENTEROLOGY

Discontinuation of Low-Dose Aspirin Therapy After Peptic Ulcer Bleeding Increases Risk of Death and Acute Cardiovascular Events

(2012) Maryam Derogar et al.   Clinical Gastroenterology and Hepatology

Esomeprazole for Prevention and Resolution of Upper Gastrointestinal Symptoms in Patients Treated With Low-dose Acetylsalicylic Acid for Cardiovascular Protection

(2012) James M. Scheiman et al.   JOURNAL OF CARDIOVASCULAR PHARMACOLOGY

Cost-effectiveness analysis: cardiovascular benefits of proton pump inhibitor co-therapy in patients using aspirin for secondary prevention

(2011) S. D. Saini et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Double-Blind Randomized Trials of Single-Tablet Ibuprofen/High-Dose Famotidine vs. Ibuprofen Alone for Reduction of Gastric and Duodenal Ulcers

(2011) Loren Laine et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Suboptimal gastroprotective coverage of NSAID use and the risk of upper gastrointestinal bleeding and ulcers: an observational study using three European databases

(2011) E. M. van Soest et al.   GUT

Prevention of peptic ulcers with esomeprazole in patients at risk of ulcer development treated with low-dose acetylsalicylic acid: a randomised, controlled trial (OBERON)

(2011) J. M. Scheiman et al.   HEART

AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2011 Update

(2011) Sidney C. Smith et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Increased risk of stroke after discontinuation of acetylsalicylic acid: A UK primary care study

(2011) L. A. Garcia Rodriguez et al.   NEUROLOGY

Incidence of gastrointestinal bleeding in patients with cardiovascular disease: buffered aspirin versus enteric-coated aspirin

(2011) Yoshikazu Hirata et al.   SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY

Underutilization of gastroprotective strategies in aspirin users at increased risk of upper gastrointestinal complications

(2010) L. E. TARGOWNIK et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Clinical trial: the incidence of NSAID-associated endoscopic gastric ulcers in patients treated with PN 400 (naproxen plus esomeprazole magnesium) vs. enteric-coated naproxen alone

(2010) J. L. Goldstein et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

The Impact of Upper Gastrointestinal Symptoms on Nonadherence to, and Discontinuation of, Low-Dose Acetylsalicylic Acid in Patients with Cardiovascular Risk

(2010) Stephen Pratt et al.   American Journal of Cardiovascular Drugs

ACCF/ACG/AHA 2010 Expert Consensus Document on the Concomitant Use of Proton Pump Inhibitors and Thienopyridines: A Focused Update of the ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use

(2010) Neena S Abraham et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Prevalence and clinical impact of Upper Gastrointestinal Symptoms in subjects treated with Low Dose Aspirin: The UGLA survey

(2010) Guillaume Cayla et al.   INTERNATIONAL JOURNAL OF CARDIOLOGY

Prescription rates of protective co-therapy for NSAID users at high GI risk and results of attempts to improve adherence to guidelines

(2009) L. LAINE et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Changing perceptions and practices regarding aspirin, nonsteroidal anti-inflammatory drugs, and cyclooxygenase-2 selective nonsteroidal anti-inflammatory drugs among US primary care providers

(2008) N. ELNACHEF et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Proton pump inhibitors reduce the long-term risk of recurrent upper gastrointestinal bleeding: an observational study

(2008) E. L. MASSÓ GONZÁLEZ et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Efficacy of Esomeprazole (20 mg Once Daily) for Reducing the Risk of Gastroduodenal Ulcers Associated With Continuous Use of Low-Dose Aspirin

(2008) Neville Yeomans et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use

(2008) Deepak L. Bhatt et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY